×
About 4,238 results

ALLMedicine Mastocytosis Center

Research & Reviews  1,803 results

Treatment of Systemic Mastocytosis With the Pulsed Dye Laser.
https://doi.org/10.1097/DSS.0000000000002430
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]; Ju EM, Patel J et. al.

May 28th, 2020 - Treatment of Systemic Mastocytosis With the Pulsed Dye Laser.|2020|Ju EM,Patel J,Burton CS,|

Midostaurin improves quality of life and mediator-related symptoms in advanced systemic...
https://doi.org/10.1016/j.jaci.2020.03.044
The Journal of Allergy and Clinical Immunology; Hartmann K, Gotlib J et. al.

May 21st, 2020 - Advanced systemic mastocytosis (advSM) is characterized by the presence of the KIT D816V mutation and pathologic accumulation of neoplastic mast cells (MCs) in various tissues, leading to severe symptoms and organ damage, eg, cytopenias, liver dys...

Development and characterization of a fully human antibody targeting SCF/c-kit signaling.
https://doi.org/10.1016/j.ijbiomac.2020.05.045
International Journal of Biological Macromolecules; Kim JO, Kim HN et. al.

May 21st, 2020 - CD117/c-kit, a tyrosine kinase receptor, plays a critical role in hematopoiesis, pigmentation, and fertility. The overexpression and activation of c-kit are thought to promote tumor growth and have been reported in various cancers, including leuke...

Trichinella spiralis-induced mastocytosis and erythropoiesis are simultaneously support...
https://doi.org/10.1371/journal.ppat.1008579
PLoS Pathogens; Inclan-Rico JM, Hernandez CM et. al.

May 18th, 2020 - Anti-helminth responses require robust type 2 cytokine production that simultaneously promotes worm expulsion and initiates the resolution of helminth-induced wounds and hemorrhaging. However, how infection-induced changes in hematopoiesis contrib...

A Rare Case of Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN) Invo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252834
The American Journal of Case Reports; Ibrahim FA, Abdulla MAJ et. al.

May 13th, 2020 - BACKGROUND Single or multiple cell line dysplasia is a characteristic feature of myelodysplastic syndrome. However, significant dysgranulopoiesis is not a feature of chronic myeloid leukemia (CML). Systemic mastocytosis (SM) with an associated hem...

see more →

Guidelines  3 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JNCCN; Gotlib J, Gerds AT et. al.

Dec 13th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/12/1500.full
Gotlib, J.

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt.

Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of t...
https://doi.org/10.1111/all.12436
Allergy Valent P, Escribano L et. al.

May 19th, 2014 - Mastocytosis is an emerging differential diagnosis in patients with more or less specific mediator-related symptoms. In some of these patients, typical skin lesions are found and the diagnosis of mastocytosis can be established. In other cases, ho...

see more →

Drugs  259 results see all →

Clinicaltrials.gov  2,105 results

Treatment of Systemic Mastocytosis With the Pulsed Dye Laser.
https://doi.org/10.1097/DSS.0000000000002430
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]; Ju EM, Patel J et. al.

May 28th, 2020 - Treatment of Systemic Mastocytosis With the Pulsed Dye Laser.|2020|Ju EM,Patel J,Burton CS,|

Midostaurin improves quality of life and mediator-related symptoms in advanced systemic...
https://doi.org/10.1016/j.jaci.2020.03.044
The Journal of Allergy and Clinical Immunology; Hartmann K, Gotlib J et. al.

May 21st, 2020 - Advanced systemic mastocytosis (advSM) is characterized by the presence of the KIT D816V mutation and pathologic accumulation of neoplastic mast cells (MCs) in various tissues, leading to severe symptoms and organ damage, eg, cytopenias, liver dys...

Development and characterization of a fully human antibody targeting SCF/c-kit signaling.
https://doi.org/10.1016/j.ijbiomac.2020.05.045
International Journal of Biological Macromolecules; Kim JO, Kim HN et. al.

May 21st, 2020 - CD117/c-kit, a tyrosine kinase receptor, plays a critical role in hematopoiesis, pigmentation, and fertility. The overexpression and activation of c-kit are thought to promote tumor growth and have been reported in various cancers, including leuke...

Ranitidine - ranitidine solution-Hi-Tech Pharmacal Co., Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7485b07-7ac0-44fe-a713-1e066c9043a8

May 18th, 2020 - Ranitidine is indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks....

Trichinella spiralis-induced mastocytosis and erythropoiesis are simultaneously support...
https://doi.org/10.1371/journal.ppat.1008579
PLoS Pathogens; Inclan-Rico JM, Hernandez CM et. al.

May 18th, 2020 - Anti-helminth responses require robust type 2 cytokine production that simultaneously promotes worm expulsion and initiates the resolution of helminth-induced wounds and hemorrhaging. However, how infection-induced changes in hematopoiesis contrib...

see more →

News  63 results

Gene-targeting therapy shown to reduce mastocytosis symptoms
https://www.mdedge.com/familymedicine/article/219888/asthma/gene-targeting-therapy-shown-reduce-mastocytosis-symptoms?channel=39313
CHEST Physician; Richard Mark Kirkner

Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.

Update on Rosacea Classification and Its Controversies
https://www.mdedge.com/dermatology/article/204310/rosacea/update-rosacea-classification-and-its-controversies/page/0/1?channel=291

Jul 9th, 2019 - However, the Expert Committee still did not define either the length of time of flushing or nontransient erythema. It also did not specify convex surfaces of the face with periocular sparing as the characteristic pattern or provide additional info.

Inhibitor can improve symptoms of systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/190755/cythemias/inhibitor-can-improve-symptoms-systemic-mastocytosis?channel=50517
Jen Smith

Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.

A Case of Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disease at VA Pittsburgh Healthcare System
https://www.mdedge.com/fedprac/avaho/article/174895/lymphoma-plasma-cell-disorders/case-systemic-mastocytosis-associated
Liman AD, Gandhi A et. al.

Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.

Avapritinib produces durable responses in SM
https://www.mdedge.com/hematology-oncology/article/184888/leukemia-myelodysplasia-transplantation/avapritinib-produces-durable
HT Staff

Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.

see more →

Patient Education  5 results see all →